AG0302-COVID19 Uses, Dosage, Side Effects and more
Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081).
| Trade Name | AG0302-COVID19 |
| Generic | AG0302-COVID19 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
